4D Molecular Therapeutics, Inc. (FDMT) Stock

4D Molecular Therapeutics, Inc. (FDMT) is a Healthcare stock trading at $9.64 (as of 2026-06-18), with a market capitalization of $514.35M and a trailing P/E of -3.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

4D Molecular Therapeutics, Inc. develops gene therapy product candidates using adeno-associated virus vectors. Its clinical-stage portfolio includes programs in ophthalmology, cardiology, and pulmonology, with Phase 1/2 candidates 4D-125, 4D-110, and 4D-310, and IND candidates 4D-150 and 4D-710.

Valuation — source: SEC EDGAR (first-party)
Price	$9.64
Market Cap	$514.35M
P/E Ratio	-3.8
EV / EBITDA	-2.5
Price / Book	1.12
Price / Sales	5.72
DCF Value (model)	$-31.35
DCF Upside vs Price	-425.0%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$85.21M
Net Margin	-164.4%
Return on Equity	-35.6%
Current Ratio	9.34
Revenue Growth (YoY)	230194.6%
EPS Growth (YoY)	-18.8%
FCF Growth (YoY)	-20.8%

Financial Health — source: SEC EDGAR
Altman Z-Score	3.69 (safe)

Valuation vs Sector & Industry
Stock P/E	-3.8
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-118.0%
vs Industry	-122.1%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	JANUS HENDERSON GROUP PLC ($48.87M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	David H. Kirn
Employees	227
Country	US
IPO Date	2020-12-11

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.